Table 1.
The basic characteristics of the included trials
| Author | Year | N (inter/cont) | Age (inter) | Age (cont) | Intervention |
Control | Duration | Study design | |
|---|---|---|---|---|---|---|---|---|---|
| Type | Dosage of inulin | ||||||||
| Cai X(30) | 2018 | 99 (49/50) | 60.94 ± 5.35 | 60.16 ± 5.84 | Milk powder co-supplemented with inulin and resistant dextrin | 10–30 g | Milk powder | 12 weeks | Double-blinded placebo RCT |
| Dehghan P(26) | 2013 | 54 (24/25) | 47.8 ± 10.1 | 48.7 ± 9.7 | Inulin | 10 g | Maltodextrin | 8 weeks | Triple-blinded placebo RCT |
| Dehghan P(27) | 2014 | 54 (27/25) | 48.4 ± 8.4 | 48.7 ± 9.7 | Oligofructose-enriched inulin | 10 g | Maltodextrin | 8 weeks | Triple-blinded placebo RCT |
| Dehghan P(40) | 2016 | 54 (27/22) | 48.07 ± 8.7 | 48.61 ± 9.16 | Oligofructose-enriched inulin | 10 g | Placebo | 2 months | Double-blinded placebo RCT |
| Ghavami A(38) | 2018 | 46 (23/23) | 41.5 ± 6.27 | 42.73 ± 5.95 | HP inulin | 10 g | Placebo | 6 weeks | Double-blinded placebo RCT |
| MA Farhangi(37) | 2016 | 54 (27/22) | 48.07 ± 8.7 | 48.61 ± 9.16 | Chicory enriched inulin | 10 g | Placebo | 2 months | Double-blinded placebo RCT |
| Neda Roshanravan(31) | 2017 | 60 (15/15) | 51.47 ± 6.46 | 51.73 ± 8.44 | Inulin powder + butyrate placebo | 10 g | Butyrate placebo + inulin placebo | 45 days | Double-blinded placebo RCT |
| Shakeri H(41) | 2014 | 78 (26/26) | 52.3 ± 10.8 | 52.3 ± 8.2 | Synbiotic bread (Lactobacillus sporogenes + inulin) | 8.4 g | Probiotic bread (Lactobacillus sporogenes) | 8 weeks | Double-blinded RCT |
| Tajabadi-Ebrahimi M(39) | 2014 | 81 (27/27) | 51.3 ± 10.4 | 53.4 ± 7.5 | Synbiotic bread (Lactobacillus sporogenes + inulin) | 8.4 g | Probiotic bread (Lactobacillus sporogenes) | 8 weeks | Double-blinded placebo RCT |
HP, high performance; RCT, randomized controlled trial.